• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>APMIS: Acta Pathologica, Microbiologica et Immunologica Scandinavica >Genetic variant of IL28B rs12979860, as predictive marker of interferon-based therapy in Pakistani population
【24h】

Genetic variant of IL28B rs12979860, as predictive marker of interferon-based therapy in Pakistani population

机译：IL28B rs12979860的遗传变异，作为巴基斯坦人群基于干扰素的治疗的预测指标

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Hepatitis C virus (HCV) genotypes and genetic variants of interleukin 28B (IL28B) are significantly associated with interferon plus ribavirin treatment of HCV infection. We investigated the distribution of HCV genotypes and single-nucleotide polymorphisms (SNPs) of IL28B (rs12979860 and rs8099917) in Pakistani population. IL28B genotyping was performed by allele-specific PCR and restriction fragment length polymorphism PCR in 140 chronic hepatitis C patients (CHC) and 120 healthy controls. HCV genotype 3 (HCVG3) was the most prevalent genotype, 71.4% (n=100/140) and with the highest treatment response of 90% (n=90/100). The overall treatment response of all the HCV genotypes was 82% (n=115/140). The distribution of IL28B rs12979860CC genotype in treatment responder and non-responder groups was 40.8% (n=47/115) and 16% (n=4/25) respectively. IL28B rs12979860CC genotype demonstrated a significant correlation (p=0.019) with interferon-based therapy of HCV infection. However, there was no observed association of IL28B rs8099917 polymorphism with treatment response in CHC patients (p=0.264). In conclusion, HCV genotypes and IL28B rs12979860 are predictive markers for the efficiency of interferon plus ribavirin combinational therapy of HCV infection. We recommend the inclusion of testing for these markers in the clinical criteria for decision making for HCV therapy in Pakistani population.
机译：丙型肝炎病毒（HCV）基因型和白介素28B（IL28B）的遗传变异与干扰素加利巴韦林治疗HCV感染显着相关。我们调查了巴基斯坦人群中IL28B（rs12979860和rs8099917）的HCV基因型和单核苷酸多态性（SNP）的分布。通过等位基因特异性PCR和限制性片段长度多态性PCR对140例慢性丙型肝炎患者（CHC）和120例健康对照进行IL28B基因分型。 HCV基因型3（HCVG3）是最流行的基因型，占71.4％（n = 100/140），最高的治疗反应为90％（n = 90/100）。所有HCV基因型的总体治疗反应为82％（n = 115/140）。 IL28B rs12979860CC基因型在治疗反应者和非反应者组中的分布分别为40.8％（n = 47/115）和16％（n = 4/25）。 IL28B rs12979860CC基因型与基于干扰素的HCV感染治疗表现出显着相关性（p = 0.019）。但是，在CHC患者中未观察到IL28B rs8099917多态性与治疗反应的相关性（p = 0.264）。总之，HCV基因型和IL28B rs12979860是干扰素加利巴韦林联合治疗HCV感染效率的预测指标。我们建议将这些标志物的测试纳入临床标准中，以决定巴基斯坦人群的HCV治疗决策。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号